Is Thiotepa safe for babies and kids?
Context-dependent for kids(Babies-specific data is limited; this page draws from human pregnant context.) Pregnancy alters the metabolism and distribution of Thiotepa, potentially increasing fetal exposure. The developing embryo/fetus is vulnerable during organogenesis (weeks 3-8) and neurological development. Placental transfer should be assumed.
What is thiotepa?
The IUPAC name is tris(aziridin-1-yl)-sulfanylidene-lambda5-phosphane.
Also known as: tris(aziridin-1-yl)-sulfanylidene-lambda5-phosphane, THIO-TEPA, Triethylenethiophosphoramide, Thiophosphamide.
- IUPAC name
- tris(aziridin-1-yl)-sulfanylidene-lambda5-phosphane
- CAS number
- 52-24-4
- Molecular formula
- C6H12N3PS
- Molecular weight
- 189.22 g/mol
- SMILES
- C1CN1P(=S)(N2CC2)N3CC3
- PubChem CID
- 5453
Risk for babies
Context-dependentPregnancy alters the metabolism and distribution of Thiotepa, potentially increasing fetal exposure. The developing embryo/fetus is vulnerable during organogenesis (weeks 3-8) and neurological development. Placental transfer should be assumed.
No specific reproductive toxicity data identified, but pregnancy-specific safety data is limited for most chemicals. Precautionary minimization of exposure is recommended.
Risk for pregnant and nursing people
Context-dependentPregnancy alters the metabolism and distribution of Thiotepa, potentially increasing fetal exposure. The developing embryo/fetus is vulnerable during organogenesis (weeks 3-8) and neurological development. Placental transfer should be assumed.
No specific reproductive toxicity data identified, but pregnancy-specific safety data is limited for most chemicals. Precautionary minimization of exposure is recommended.
Regulatory consensus
7 regulatory and scientific bodies have classified Thiotepa. The classifications differ — that's the data.
| Agency | Year | Classification | Notes |
|---|---|---|---|
| IARC | 1990 | Group 1 | |
| US EPA | 2000 | probable human carcinogen (Group B2) | |
| EPA CTX / NTP RoC | — | Known Human Carcinogen | |
| EPA CTX / IARC | — | Group 1 - Carcinogenic to humans | |
| EPA CTX / CalEPA | — | Known human carcinogen | |
| EPA CTX / Genetox | — | Genotoxicity: positive (Ames: positive, 23 positive / 0 negative reports) | |
| EPA CTX / Genetox | — | Genotoxicity: positive (Ames: positive, 23 positive / 0 negative reports) |
Regulators apply different standards of evidence — animal-data weighting, exposure-pattern assumptions, epidemiological power thresholds — which is why two scientific bodies can review the same data and reach different conclusions. The disagreement is the data.
Where kids encounter thiotepa
- Industrial Facilities — Manufacturing plants, Chemical storage areas, Waste treatment sites
- Occupational Environments — Factories, Warehouses, Transportation vehicles
Safer alternatives
Lower-risk approaches that achieve a similar outcome to Thiotepa:
-
Safer process chemistry; Green chemistry alternatives; Exposure controls
Trade-offs: Requires R&D investment to redesign synthesis routes; may reduce yield or throughput initially; long-term benefits include reduced waste treatment costs, regulatory compliance, and worker safety; 12 Principles of Green Chemistry framework available.Relative cost: 2-5×
Frequently asked questions
What products contain thiotepa?
Thiotepa appears in: Manufacturing plants (Industrial facilities); Chemical storage areas (Industrial facilities); Factories (Occupational environments); Warehouses (Occupational environments).
Why do regulators disagree about thiotepa?
Thiotepa has been classified by 7 agencies including IARC, US EPA, EPA CTX / NTP RoC, EPA CTX / IARC, EPA CTX / CalEPA, with differing conclusions. Regulators apply different standards of evidence (animal data weighting, exposure-pattern assumptions, epidemiological power thresholds), which is why two scientific bodies can review the same data and reach different conclusions. See the regulatory consensus table on this page for the full picture.
See Thiotepa in the baby app
Look up products containing thiotepa, compare to alternatives, and explore the full data record.
Open in baby View raw API dataSources (2)
- IARC Monographs Volume 50: Pharmaceutical Drugs — Thiotepa Group 1; Leukemia in Breast/Ovarian Cancer Patients; Trifunctional Aziridine Alkylation; CNS Penetration; Intravesical Bladder Cancer Use; CYP3A4/2B6 TEPA Activation (1990) — iarc_monograph
- US EPA Thiotepa: Group B2 Probable Carcinogen; NIOSH Hazardous Drug; Intravesical Systemic Absorption Myelosuppression; CNS Lymphoma Transplant Conditioning; Nurse Dermal Exposure Biomonitoring; Hydrophilic Non-Bioaccumulative (2000) — regulatory
Reference data, not professional advice. Aggregates publicly available regulatory and scientific data; not a substitute for veterinary, medical, legal, or regulatory advice. Why we built ALETHEIA →